Cell Proliferation and the Principles of Cancer Therapy

Author(s):  
W. M. Gregory
2021 ◽  
Author(s):  
Bin Zhang ◽  
Zichen Xu ◽  
Wen Zhou ◽  
Zhikun Liu ◽  
Jian Zhao ◽  
...  

Hypoxia is a major obstacle for cancer therapy due to its association with cell proliferation, tumor distant metastasis, and treatment resistance. In this study, a hypoxia-activated bifunctional prodrug (CC5) was...


2019 ◽  
Vol 9 (1-s) ◽  
pp. 408-415 ◽  
Author(s):  
Rupalben Kaushalkumar Jani ◽  
Gohil Krupa

In nanomedicines, currently a wide array of reported nanoparticle systems is being explored by targeting schemes which suggests great potential of targeted delivery to revolutionize cancer therapeutics. This review  gives insight into recent  challenges in modification of nanoparticle systems for enhanced cancer therapy  acknowledged by researchers to date and also outlines different major targeting strategies of nanoparticle systems that have been utilized for the delivery of therapeutics or imaging agents, targeting ligand and cross-linking agent to cancer  which was divided into three sections: 1) Angiogenesis associated targeting, 2) Uncontrolled cell proliferation targeting and 3) Tumor cell targeting. Keywords: nanoparticles, tumor cells, active targeting, targeting strategies, targeting ligands


2021 ◽  
Author(s):  
Ramesh L. Sawant ◽  
Jyoti B. Wadekar ◽  
Rushikesh D. Ukirde ◽  
Ganesh D. Barkade

Polo-like kinase 1(Plk1) plays an important role in the inhibition of cell proliferation and which is come under the family of serine/threonine-protein kinase. Which is a highly specific target for cancer therapy. In some clinical studies, Plk1 has been identified as a target for cancer. Currently, so many scientists are working on the development of the Plk1 inhibitors and so many scientists and researchers thinking about working on it. Recent strategy for Plk1 inhibition is the development of small molecule inhibitors which will inhibit the Plk1 through the ATP-binding site of the Plk. Now new generation Plk1 inhibitors being tested clinically which are targeting polo box domain. This review highlights the recent progress made in the development of Plk1 inhibitors as anticancer agents.


2021 ◽  
Vol 14 (3) ◽  
pp. 1481-1500
Author(s):  
Nelofar Sediqi ◽  
Aisyah Hasyila Jahidin ◽  
Mizaton Hazizul Hasan ◽  
Yuslina Zakaria

Cancer is one of the most disastrous diseases that leads to a serious threat to millions of people’s health worldwide. Cancer is distinguished by multiple common criteria, known as the “cancer hallmarks" which calcium signaling has either direct or indirect correlation with each of them. An emerging body of evidence suggests that two-pore channels/calcium signaling machinery has a crucial role in the promotion of diverse aspects of cancer, particularly in several cancer hallmarks including cell proliferation, angiogenesis, migration, invasion, metastasis, and metabolic reprogramming. Recent findings linked two-pore channels/calcium signaling machinery with autophagy, chemoresistance, and patients' survival in cancer. The present review provides current findings on the roles of two-pore channels in cancer, particularly in several cancer hallmarks, autophagy, and chemoresistance. Furthermore, a specific focus on recent data concerning the two-pore channels antagonists and novel inhibitors is discussed. This review will furnish readers with a more in-depth understanding of the significance of two-pore channel calcium signalling in cancer and its potential as a druggable target for cancer therapy


Author(s):  
Atefeh Jalali ◽  
Farid Dabaghian ◽  
Mohammad M. Zarshenas

Background: Cancer is a serious and growing global health issue worldwide. In the cancerous cells, the normal cell cycle has been disrupted via the series of irreversible changes. Recently, the investigations on herbal medicine and clarifying the phytochemicals potential in treat cancer has been increased. The combination of phytochemicals with conventional approaches in cancer treatment can improve outcomes via advancing cell death, restraining cell proliferation and invasion, sensitizing cancerous cells, and promoting the immune system. Therefore, phytochemicals can be introduced as relevant complementary medicaments in cancer therapy. Peganum harmala L. (Zygophyllaceae) as a valuable medicinal herb, possesses various alkaloid ingredient. Objective: Pointing to the importance of new avenues for cancer management and of P. harmala convincing effect in this field, this review strived to collect a frame to epitome possible scopes for the development of novel medicines in cancer treatment. Methods: Keywords "Peganum harmala" and cancer, or chemotherapy, or anti-neoplasm were searched through the "Scopus", database up to the 29th of February 2020. Papers linking to agriculture, chemistry, environmental, and genetics sciences were omitted and, papers centered on cancer were selected. Result and Discussion: In the current study, 42 related papers to cancer treatment and 22 papers on alkaloid bioactive components are collected from 72 papers. The β-carboline alkaloids derived from P. harmala, especially harmine, demonstrate notable anticancer properties by targeting apoptosis, autophagy, abnormal cell proliferation, angiogenesis, metastasis, and cytotoxicity. Based on the collected information, P. harmala holds significant anticancer activity. Considering the mechanism of the various anticancer drugs and their acting similarity to P. harmala, the alkaloids derived from this herb, particularly harmine, can introduce as a novel anticancer medicine solely or in adjuvant cancer therapy.


2018 ◽  
Vol 66 (8) ◽  
pp. 1083-1087 ◽  
Author(s):  
Shahla Shojaei ◽  
Javad Alizadeh ◽  
James Thliveris ◽  
Navid Koleini ◽  
Elissavet Kardami ◽  
...  

Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents.


Sign in / Sign up

Export Citation Format

Share Document